Results 11 to 20 of about 337 (145)

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2021
This analysis was conducted to assess exposure–response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor.
Ophelia Yin, Hamim Zahir, Jonathan French, Daniel Polhamus, Xiaoning Wang, Michiel van deSande, William D. Tap, Hans Gelderblom, Andrew J. Wagner, John H. Healey, Jonathan Greenberg, Dale Shuster, Silvia Stacchiotti   +12 more
doaj   +6 more sources

Pexidartinib: First Approval [PDF]

Drugs, 2019
Pexidartinib (TURALIO™) is an orally administered small molecule tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation (FLT3-ITD).
Yvette Lamb (6930427)
openaire   +3 more sources

Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors [PDF]

The Oncologist, 2020
Abstract Background Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. Materials, and Methods
Lewis, James H., Gelderblom, Hans, van de Sande, Michiel, Stacchiotti, Silvia, Healey, John H., Tap, William D., Wagner, Andrew J., Pousa, Antonio Lopez, Druta, Mihaela, Lin, Chia-Chi, Baba, Hideo Andreas, Choi, Youngsook, Wang, Qiang, Shuster, Dale E., Bauer, Sebastian   +14 more
core   +9 more sources

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors [PDF]

Cancer, 2020
BackgroundThe objective of this study was to report on the long‐term effects of pexidartinib on tenosynovial giant cell tumor (TGCT).MethodsThis was a pooled analysis encompassing 3 pexidartinib‐treated TGCT cohorts: 1) a phase 1 extension study (NCT01004861; 1000 mg/d; n = 39), 2) ENLIVEN patients randomized to pexidartinib (1000 mg/d for 2 weeks and ...
Hans Gelderblom, Andrew J. Wagner, William D. Tap, Emanuela Palmerini, Zev A. Wainberg, Jayesh Desai, John H. Healey, Michiel A. J. van de Sande, Nicholas M. Bernthal, Eric L. Staals, Charles G. Peterfy, Anna Maria Frezza, Henry H. Hsu, Qiang Wang, Dale E. Shuster, Silvia Stacchiotti   +15 more
openaire   +7 more sources

Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN [PDF]

Clinical Orthopaedics & Related Research, 2022
Abstract Background The double-blind, randomized, placebo-controlled phase 3 study of orally administered PLX3397 in patients with pigmented villonodular synovitis or giant cell tumor of the tendon sheath (ENLIVEN) showed that pexidartinib provides a robust objective tumor response in adults with tenosynovial giant ...
Healey, J.H., Tap, W.D., Gelhorn, H.L., Ye, X., Speck, R.M., Palmerini, E., Stacchiotti, S., Desai, J., Wagner, A.J., Alcindor, T., Ganjoo, K., Martin-Broto, J., Wang, Q., Shuster, D., Gelderblom, H., Sande, M. van de   +15 more
openaire   +4 more sources

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors [PDF]

Therapeutic Advances in Medical Oncology, 2019
Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors. Patients and Methods:
Robert Wesolowski, Neelesh Sharma, Laura Reebel, Mary Beth Rodal, Alexandra Peck, Brian L. West, Adhirai Marimuthu, Paul Severson, David A. Karlin, Afshin Dowlati, Mai H. Le, Lisa M. Coussens, Hope S. Rugo   +12 more
doaj   +2 more sources

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel [PDF]

npj Breast Cancer, 2019
AbstractPexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin’s lymphoma, and glioblastoma. Here, we report a case of severe drug-induced
Piawah, Sorbarikor, Hyland, Colby, Umetsu, Sarah E, Esserman, Laura J, Rugo, Hope S, Chien, A Jo   +5 more
openaire   +6 more sources

Pexidartinib Upfront in a Case of Tenosynovial Giant Cell Tumor: Proof of Concept for a Treatment Paradigm Shift

Oncology and Therapy
Background Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive tumor of the joints, bursa, and tendon sheath that can cause considerable pain and substantial morbidity.
Emanuela Palmerini, Giuliano Peta, Gianmarco Tuzzato   +2 more
doaj   +2 more sources

Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis [PDF]

Endocrinology
Abstract Endometriosis is a common and debilitating disease, affecting ∼170 million women worldwide. Affected patients have limited therapeutic options such as hormonal suppression or surgical excision of the lesions, though therapies are often not completely curative.
Timothy N Dunn, Dominique I Cope, Suni Tang, Tirupataiah Sirupangi, Sydney E Parks, Zian Liao, Fei Yuan, Chad J Creighton, Ramya P Masand, Linda Alpuing Radilla, Xiaoming Guan, Laura Detti, Diana Monsivais, Martin M Matzuk   +13 more
openaire   +4 more sources

Pexidartinib Inhibits Macrophage Senescence Through Glycolysis in Periodontitis Microenvironment

International Dental Journal
Objectives: Periodontitis, a chronic inflammatory condition, is caused by complex interactions between periodontopathic bacteria and the local innate immune response. Macrophage senescence, a pivotal contributor to immune dysfunction, has been implicated
Jifan Zhan, Jiabing Kang, Yan Wei, Tianjiao Xiao, Hui Fang, Li Li, Yiting Yuan, Yongchun Zhang, Jie Zhang, Ai Tian   +9 more
doaj   +3 more sources